^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD122 agonist

    Related drugs:
    2d
    T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (clinicaltrials.gov)
    P1, N=36, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Site plans to become a site for a multicenter study of this therapy
    Trial termination • IO biomarker
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Zuplenz (ondansetron oral dispersible film)
    6d
    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=195, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    10d
    Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    14d
    Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=27, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    25d
    Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (clinicaltrials.gov)
    P1/2, N=8, Terminated, Alaunos Therapeutics | N=180 --> 8 | Active, not recruiting --> Terminated; Funding
    Enrollment change • Trial termination • IO biomarker
    |
    Proleukin (aldesleukin)
    2ms
    Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD) (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, University of Oxford | Trial completion date: Sep 2022 --> Sep 2026
    Trial completion date
    |
    Proleukin (aldesleukin)
    2ms
    A quantitative systems pharmacology model to inform clinical translation of dynamic PKPD relationships of engineered IL-15. (PubMed, Eur J Pharm Sci)
    In this work, we develop a quantitative systems pharmacology (QSP) model to capture the dynamics of lymphocyte expansion in response to three engineered IL-15/IL-15Rα therapeutics: a potency engineered Fc-fusion referred to as Efbalropendekin alfa; a heterodimeric, PD-1 targeted cytokine assessed in non-clinical studies (PD1/IL15 TaCk); and an anti-respiratory syncytial virus targeted cytokine that serves as a non-binding isotype control (RSV/IL15 TaCk)...Finally, we leverage our QSP modeling framework to generate virtual cohorts with various translational scenarios to make clinical PK/PD predictions in response to PD1/IL15 TaCk treatment. Overall, the systems modeling presented herein offers a novel approach to integrate non-clinical datasets, aid in translation, and support dosing decisions for cytokine-based therapies that activate the immune system and display a dynamic PK/PD relationship.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL15 (Interleukin 15)
    2ms
    Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma (clinicaltrials.gov)
    P=N/A, N=19, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2025
    Trial completion • Trial completion date
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    3ms
    A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma. (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Focus V (anlotinib) • doxorubicin hydrochloride • bempegaldesleukin (NKTR-214)
    4ms
    BelieveIT-201: TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=27, Terminated, Ascendis Pharma A/S | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)
    4ms
    Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1, N=86, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TruSight Oncology 500 Assay
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    5ms
    Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=78, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2027 --> Sep 2031 | Trial primary completion date: Sep 2026 --> Sep 2031
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)